Table 11 Effect of δ-tocotrienol on canonical pathways (33) of IPA ingenuity canonical pathways analysis (360) in hepatitis C patients
# | Ingenuity Canonical Pathways (Fold Change Expression) | -log (p-value) | Ratio | Z-Score | Molecules |
|---|---|---|---|---|---|
1 | EIF2 Signaling; Eukaryotic translation initiation factors (221) | 36.900 | 0.303 | -5.692 | RPL7A,EIF3G,RPL13A,RPL32,RPS24,RPL37A,RPL23,RPL26,RPS13 |
2 | Regulation of eIF4 and p70S6K signaling (157) | 13.300 | 0.210 | 0.000 | PPP2R5E, EIF3G, RPS26 |
3 | Protein ubiquitination pathway (265) | 3.130 | 0.091 | #NUM! | UBE2J1, USP19, UBA52 |
4 | mTOR signaling; Mammalian target of rapamycin (201) | 12.900 | 0.184 | -2.138 | PPP2R5E, EIF3G, RPS26 |
5 | Type I Diabetes Mellitus Signaling (111) | 5.760 | 0.162 | -2.496 | NFKB1,MAP3K5,JAK2,HLA-DQB1,IFNGR2,TNFRSF1B,PIAS1,TRADD |
6 | Th1 and Th2 Activation Pathway (185) | 5.640 | 0.130 | #NUM! | NFKB1,JAK2,NOTCH1,HLA-DQB1,IFNGR2,PIK3R1,HLA-DRA |
7 | Interferon Signaling (36) | 4.700 | 0.250 | -2.333 | IFNGR1,OAS1,IFIT1,JAK2,IFITM1,IFNGR2,IFITM2,PIAS1,PSMB8 |
8 | Role of IL-17F (44) | 3.960 | 0.205 | -3.000 | NFKB1,ATF4,CREB1,RPS6KA3,CXCL1,MAPK1,CXCL8,RPS6KA4 |
9 | IL-8 Signaling (197) | 3.320 | 0.102 | -4.123 | NFKB1,GNA13,GNB4,RACK1,VEGFA,MYL12B,PIK3R1,ARRB2,NCF2 |
10 | NF-κB Signaling (181) | 2.940 | 0.099 | -4.243 | GSK3B,SIGIRR,NFKB1,CSNK2B,TNFRSF1B,IL1R2,PIK3R1,TRADD |
11 | IL-17A Signaling in Fibroblasts (35) | 2.400 | 0.171 | #NUM! | GSK3B,NFKB1,CEBPD,CEBPB,MAPK1,TRAF6 |
12 | IL-6 Signaling (128) | 2.360 | 0.102 | -3.051 | NFKB1,JAK2,CSNK2B,TNFRSF1B,VEGFA,IL1R2,PIK3R1,CXCL8,FRS2 |
13 | Induction of Apoptosis by HIV1 (61) | 2.280 | 0.131 | -2.828 | CXCR4,NFKB1,MAP3K5,TNFRSF1B,CASP3,TRADD,RIPK1,SLC25A13 |
14 | HMGB1 Signaling (133) | 2.220 | 0.098 | -3.606 | OSM,NFKB1,IFNGR2,TNFRSF1B,PIK3R1,SP1,CXCL8,IFNGR1,HMGB1 |
15 | PPAR Signaling (95) | 2.040 | 0.105 | 1.897 | NFKB1,TNFRSF1B,PTGS2,IL18RAP,MAPK1,IL1R2,HSP90AB1,SCAND1 |
16 | IL-10 Signaling (69) | 1.960 | 0.116 | #NUM! | NFKB1,IL18RAP,MAPK1,IL1R2,SP1,FCGR2A,TRAF6,IL10RA |
17 | iNOS Signaling (45) | 1.860 | 0.133 | -2.449 | IFNGR1,NFKB1,JAK2,IFNGR2,MAPK1,TRAF6 |
18 | Insulin Receptor Signaling (141) | 1.650 | 0.085 | -1.508 | GSK3B,PPP1CC,PTEN,JAK2,GYS1,PDE3B,FRS2,MAPK1,GSK3A |
19 | p53 Signaling (111) | 1.600 | 0.090 | 0.000 | GSK3B,DRAM1,PTEN,HIF1A,FRS2,ATR,ST13,PIK3R1,PIAS1,PCNA |
20 | Role of IL-17A in Arthritis (69) | 1.490 | 0.101 | #NUM! | NFKB1,FRS2,PTGS2,CXCL1,MAPK1,PIK3R1,CXCL8 |
21 | Toll-like Receptor Signaling (76) | 1.300 | 0.092 | -1.000 | SIGIRR,TLR8,UBA52,NFKB1,MAP3K1,MAPK1,TRAF6 |
22 | IL-1 Signaling (92) | 1.300 | 0.087 | -2.449 | GNAQ,NFKB1,GNA13,GNB4,RACK1,MAP3K1,MAPK1,TRAF6 |
23 | Apoptosis Signaling (90) | 0.987 | 0.078 | -0.378 | NFKB1,MAP3K5,BCL2L11,BCL2A1,TNFRSF1B,MAPK1,CASP3 |
24 | PDGF Signaling (90) | 0.987 | 0.078 | -2.646 | ABL1,JAK2,CSNK2B,MAP3K1,FRS2,MAPK1,PIK3R1 |
25 | Type II Diabetes Mellitus Signaling (128) | 0.944 | 0.070 | -2.333 | NFKB1,MAP3K5,TNFRSF1B,MAP3K1,FRS2,CEBPB,MAPK1,PIK3R1 |
26 | IL-15 Signaling (76) | 0.904 | 0.107 | #NUM! | NFKB1,JAK2,TXK |
27 | autophagy (62) | 0.859 | 0.081 | #NUM! | CTSW,ATG3,ATG5,CTSC,LAMP2 |
28 | IL-2 Signaling (64) | 0.818 | 0.078 | -2.000 | CSNK2B,FRS2,MAPK1,PIK3R1,IL2RG |
29 | PPARα/RXRα Activation (180) | 0.759 | 0.061 | 3.000 | TGS1,GNAQ,TGFBR2,NFKB1,JAK2,IL18RAP,MAPK1,MED12,IL1R2 |
30 | TNFR1 (32) | 2.210 | 0.140 | -2.646 | NFKB1,MAP4K2,MAP3K1,PAK1,CASP3,TRADD,RIPK1 |
31 | STAT3 Pathway (74) | 0.641 | 0.068 | -1.342 | TGFBR2,JAK2,MAPK1,PTPN6,IGF2R |
32 | Nitric Oxide Signaling in the Cardiovascular System (113) | 0.633 | 0.062 | -2.646 | ITPR2,VEGFA,PDE3B,FRS2,MAPK1,PIK3R1,HSP90AB1 |
33 | Osteoarthritis Pathway (210) | 3.370 | 0.100 | -2.524 | NFKB1,CREB1,NOTCH1,TNFRSF1B,VEGFA,KEF1,IL-1R2,mir-140 |